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A Ab bs st tr ra ac ct t
Hereditary diffuse gastric cancer (HDGC) is the only known predisposition syndrome dominated by carcinoma
of the stomach and with a recognised genetic cause. Germline mutations in the E-cadherin gene (CDH1) 
co-segregate with the disease in about half of the families with multiple diffuse gastric cancer. In these families,
identification of the CDH1 mutation allows for clinical measures to be taken. Importantly, clinical intervention
is likely to be therapeutic and associated with tolerable morbidity. This review is thus aimed at providing a current
overview of the clinical management and the underlying biology of HDGC. 
I In nt tr ro od du uc ct ti io on n
Among the familial forms of gastric carcinoma,
hereditary diffuse gastric cancer (HDGC) is the only known
cancer predisposition syndrome where an underlying genetic
cause has been defined. Based on linkage and mutational
analysis, germline mutations affecting the gene coding for
the cell-cell adhesion molecule E-cadherin (CDH1) were
shown in 1998 to be responsible for the high incidence of
multi-generational diffuse gastric cancer (DGC) in a large
New Zealand Maori family [1]. Subsequently, CDH1
germline mutations have been found in over 90 families 
of diverse ethnicity but sharing a history of DGC (Table 1).
1 1. .   C CD DH H1 1 m mu ut ta at ti io on ns s
To date, 81 different germline mutations have been
identified throughout the entire CDH1 coding region
including intronic splice site sequences (Table 1; refs 
[1-25]). No major hot spots are apparent, though the
1137G>A and 1901C>T mutations have been detected
in six and five different families, respectively (Table 1). The
first founder mutation surrounded by an ancestral CDH1
haplotype has recently been reported in four families from
Newfoundland [2]. So far, no genotype-phenotype
correlations are evident; however, available data support
the possibility that different mutations may impact disease
spectrum and penetrance [2, 14, 24, 26].
In contrast to other cancer predisposition syndromes
such as familial adenomatous polyposis, only about
50% of CDH1 germline mutations are completely
inactivating (frameshift or nonsense, Table 1). Splice-
site and missense mutations contribute the remaining
20 and 30%, respectively, to the mutational spectrum,
suggesting that reduced rather than lost E-cadherin
activity may be sufficient for disease initiation. Since
the functional consequences of amino acid substitutions
are not straightforward, aggregation and invasion
assays are being used to assess the impact of missense
mutations on E-cadherin function in vitro [24].
CDH1 germline mutations are rare and are
estimated to account for ~1% of all gastric cancerH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(4) 184
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T Ta ab bl le e   1 1. . Identified CDH1 germline mutations
C Ca an nc ce er r    O Ot th he er r O Ot th he er r A Ag ge e   a at t   d di ia ag gn no os si is s U Un nc co on n- - C Co on n- - N No on n- - C CD DH H1 1 P Po os si it ti io on n
c c T Ty yp pe e
d d R Re ef fe er re en nc ce e
t ty yp pe e
a a c ca as se es s c ca as se es s f fi ir rm me ed d f fi ir rm me ed d    g ga as st tr ri ic c m mu ut ta at ti io on n
w wi it th h       w wi it th h    b br re ea as st t L LB BC C c ca an nc ce er rs s
b b
g ga as st tr ri ic c D DG GC C c ca an nc ce er r
c ca an nc ce er rs s
1 3G>C ex1 non 2
2 41delT ex1 del 3
3 DGC 4 2 30s, 40s, 59, 60s, 67, 70s 1 1 3 Co 45insT ex1 ins 4
4 DGC 3 54, 55, 68 1 Co, Pr, Bl, Pn 49-2A>C in2 ss 5
5 DGC 5 30, 34, 40, 53, 58, 69 Lu, Co 49-2A>G in1 ss 6
6 DGC 1 1 28 Lu, Cx 53delC ex2 del 7
7 DGC 2 27, 50 59G>A ex2 non 6
8 DGC 4 4 37, 38, 39, 40, 45, 46, 66 3 Leu 70G>T ex2 non 8
9 DGC 6 1 46, 46, 62, 69, 72, 72 Ut 185G>T ex3 mis 9
10 DGC 2 1 66, 69, 70s 2 Pr 187C>T ex3 non 10
11 DGC 1 1 28 190C>T ex3 non 8, 11
12 DGC 1 34 2 283C>T ex3 non 11
13 DGC 1 64 353C>G ex3 mis 5
14 DGC 3 15, 37, 58 1 1 372delC ex3 del 12
15 377delC ex3 del 2
16 DGC 6 40, 42, 45, 50, 55, 56 2 382delC ex3 del 13
17 515C>G ex4 mis 2
18 DGC 5 531+2T>A in4 ss 14
19 532-18C>T in4 ss 2
20 DGC 3 3 31, 46, 55 586G>T ex5 non 8
21 DGC 3 36, 48, 50 1 687+1G>A in5 ss 13
22 DGC 1 1 29 Co 715G>A ex6 mis 5
23 DGC 6 30, 33, 39, 41, 49, 63 731A>G ex6 mis 15
24 DGC 1 20 3 Co 753insG ex6 ins
e
25 HPC 1 808T>G ex6 mis 16
26 DGC 7 3 23, 29, 29, 42, 70s, 70s 1 832G>A ex6 ss 4
27 DGC 2 1 32, 33 0 892G>A ex7 mis 13
28 HGC 3 22, 44, 45, 51, 73 2 Ly, Pr 1003C>T ex7 non 17
29 DGC 28 9 14-74 1 bilateral Co 1008G>T ex7 ss 1
30 DGC 1 1 30s, 35 non-gastric 1018A>G ex8 mis 4
31 1062delG ex8 del 2
32 DGC 2 1 50, 58 0 1064insT ex8 ins 13
33 DGC 1 1 27, 64 Co 1107delC ex8 non 5
34 DGC 2 Co, DuBr 1118C>T ex8 mis 18
35 DGC 3 2 30, 32, ? 0 1134del8ins5 ex8 del+ins 13
36 DGC 2 18, 37 many 1137G>A ex8 ss 2, 5, 14
37 DGC 3 3 25, 41, 44 1137+1G>A in8 ss 8
38 DGC 4 3 17, 32, 46, 47 4 1212delC ex9 del 13
39 DGC 1 1 51 Co(SRC) 1226T>C ex9 mis 13
40 DGC 5 2 63 1243A>C ex9 mis 19
41 1285C>T ex9 mis 2
42 DGC 1 1 61, 78 1 1391-1392delTC ex10 del 5
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T Ta ab bl le e   1 1. . Identified CDH1 germline mutations 
C Ca an nc ce er r    O Ot th he er r O Ot th he er r A Ag ge e   a at t   d di ia ag gn no os si is s U Un nc co on n- - C Co on n- - N No on n- - C CD DH H1 1 P Po os si it ti io on n
c c T Ty yp pe e
d d R Re ef fe er re en nc ce e
t ty yp pe e
a a c ca as se es s c ca as se es s f fi ir rm me ed d f fi ir rm me ed d    g ga as st tr ri ic c m mu ut ta at ti io on n
w wi it th h       w wi it th h    b br re ea as st t L LB BC C c ca an nc ce er rs s
b b
g ga as st tr ri ic c D DG GC C c ca an nc ce er r
c ca an nc ce er rs s
44 DGC, LBC ND ex10 non 20
45 DGC 1 49 1460T>C ex10 mis 15
46 DGC 2 1 30s, 40s 1472_1473insA ex10 ins 4
47 DGC 60 Co 1488-1494del ex10 del 8
CGAGGAC
48 1507C>T ex10 non 2
49 DGC 2 1 56 1565+1G>T in10 ss 7
50 DGC 2 2 48, 59 1 1588insC ex11 ins 8
51 DGC 3 58, 71, 82 Co 1610delC ex11 del 21
52 DGC 1 49, 58, 73 1 bilateral Lu 1619insG ex11 ins 22
53 DGC 3 1 38-52 1 1682insA ex11 ins 2
54 DGC 1 1 19 1 Pr 1710delT ex11 del 7
55 DGC 6 30, 32, 40, 43, 56, 57 1711insG ex11 ins 10
56 DGC 2 2 44, 44 5 1 1711+5G>A in11 ss 13
57 HPC 2 46, 53, 61, 68, 75,   1 3 Pr, Co, Ut 1774G>A ex12 mis 17
76, 79, 70, 81, 85
58 DGC 2 1 35, 42 0 1779insC ex12 ins 13
59 DGC 4 27, 28, 39, 43 1792C>T ex12 non 10
60 1795A>T ex12 mis 2
61 1849G>A ex12 mis 23, 24
62 1876T>A ex12 mis 2
63 DGC 1901C>T ex12 mis 2, 5, 24
64 DGC 10 1 21-59 1913G>A ex12 non 2
65 DGC 1 1 47 0 2061delTG ex13 del 13
66 DGC 2095C>T ex13 non 1
67 LBC 2161C>G ex13 ss 2
68 DGC 3 1 38-44 2164+5G>A in13 ss 2
69 Colon 2 2 36, 70 4 2 2195G>A ex14 mis 13
70 DGC 3 2 36-49 2245C>T ex14 mis 2
71 2276delG ex14 del 2
72 DGC 3 1 44, 44, 52 2295+5G>A in14 ss 7
73 DGC 8 42, 45, 49, 57, 75, 79, 79, ? 1 2310delC ex15 del 13
74 HPC 1 64, 74, 74 2 Pr 2329G>A ex15 mis 17
75 DGC 2 2 51-63 1 2343A>T ex15 mis 2
76 DGC 6 1 16, 34, 35 2381insC ex15 ins 1
77 GC 2 52 2396C>G ex15 mis 12
78 DGC 17 2 25-80 13 3 2398delC ex15 del 2
79 DGC 6 53, 56 2494G>A ex16 mis 25
80 DGC 3 1 37, 43, 45, 60, 71 2 Lu, Ly 2440-1C>T in15 ss
e
81 DGC 1 1 Lu 2440-6C>G in15 ss 5
aDGC – diffuse gastric cancer, LBC – lobular breast cancer, HPC – hereditary prostate cancer
bBl – bladder, Co – colon, Cx – cervix, DuBr – ductal breast, Leu – leukaemia, Lu – lung, Ly – lymphoma, Pn – pancreas, Pr – prostate, Ut – uterus
cex – exon, in – intron
ddel – deletion, ins – insertion, mis – missense, non – nonsense, ss – splice site
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cases [27]. However, this appears to be the case only
for populations with a low gastric cancer incidence.
CDH1 germline mutations are detected at an even
lower frequency in high incidence countries such as
Japan, Korea, Italy and Portugal, possibly because
HDGC families are masked by chance clusters of
sporadic cases [9]. Alternatively, the presence of other
susceptibility factors such as functional CDH1
polymorphisms in high-risk areas [28] may reduce the
viability of embryos carrying CDH1 germline mutations.
2 2. .   P Pe en ne et tr ra an nc ce e   a an nd d   c cl li in ni ic ca al l   p ph he en no ot ty yp pe e
The Lauren classification distinguishes two main
histological forms of stomach cancer, the intestinal and
the diffuse type (DGC) [29]. CDH1 germline mutations
are specifically associated with diffuse-type gastric
adenocarcinoma but not with other types of stomach
cancer in the absence of a diffuse component [12].
DGC is inherited in an autosomal dominant manner
among HDGC families. Initial penetrance figures were
derived from 11 families and estimate a lifetime
cumulative DGC risk of 67 and 83% for male and
female mutation carriers, respectively [26]. A more recent
estimate based on Newfoundland families sharing 
a founder CDH1 mutation puts these numbers at 40%
for men and 63% for women [2]. It thus is probable that
the type/location of the CDH1 mutation does impact on
the actual penetrance. For example, certain missense
mutations seem to be associated with a much lower
DGC risk [5]. Similarly, the mean age at diagnosis may
vary with genotype, being 33 years in the largest known
HDGC kindred (with 28 affected members), 40 years
in the initial penetrance estimates by Pharoah, and over
50 years in families with specific missense mutations [5].
Cases of gastric cancer have been described as young
as 14 years and at 82 years in HDGC (Table 1). Varying
genetic/epigenetic backgrounds and environmental
exposures are likely to be important additional
parameters modulating the consequences of inherited
CDH1 mutations.
The only other cancer that is known to occur at an
elevated frequency in HDGC families is lobular breast
cancer (LBC). Estimates for the LBC penetrance in female
mutation carriers range from 39 [26] to 54% [2], but
these figures are derived from small numbers of cases
and have to be interpreted with caution. However, the
susceptibility towards both DGC and LBC makes sense,
as the sporadic forms of both cancers are characterised
by E-cadherin deficiency and a dis-cohesive growth
pattern [30, 31]. It appears probable that cancers at other
sites will be part of the clinical HDGC phenotype. CDH1
germline mutations have been detected in HDGC family
patients with tumours of the colorectum, lung, and
salivary glands [5]. Another example may be prostate
cancer (Table 1). In support of this, functional CDH1
polymorphisms have been shown to increase susceptibility
to this malignancy [32]. However, present numbers on
cancers other than LBC are too small to allow for any
significant association with HDGC.
3 3. .   C Cl li in ni ic ca al l   m ma an na ag ge em me en nt t
Clinical management of HDGC families is based
on presymptomatic identification of mutation carriers,
followed by prophylactic gastrectomy at the appropriate
age, or by gastroscopic surveillance and therapeutic
gastrectomy when cancer has been detected. Clinical
guidelines have been published [13, 27, 33, 34] and
are recommended for a more comprehensive overview
of patient management.
3 3..1 1  C Cl li in ni ic ca al l  c cr ri it te er ri ia a,,  m mu ut ta at ti io on n  i id de en nt ti if fi ic ca at ti io on n  a an nd d  p pr re es sy ym mp pt to om ma at ti ic c
t te es st ti in ng g
The first step is the identification of a deleterious
CDH1 germline mutation in a suspected HDGC family.
Clinical criteria have been developed that select for
families likely to harbour a CDH1 mutation. The original
criteria as proposed by the International Gastric Cancer
Linkage Consortium (IGCLC) [33] are being presently
used in a more relaxed version which requires two gastric
cancer cases in 1
st/2
nd degree relatives with at least one
documented tumour of diffuse histology and diagnosed
before the age of 50 years [13, 27, 34]. CDH1 germline
mutations are identified in about 50% of families meeting
the above criteria. Brooks-Wilson et al. [13] have
proposed a more extended set of criteria to include
families that have a smaller chance of carrying mutations.
Even when applying these criteria, unusual families with
a germline mutation can be missed [5]. In addition, the
chance of finding a mutation in an isolated case with
early onset DGC is still 10% [34]. Therefore,
comprehensive CDH1 mutation screening requires
inclusion of borderline families and cases into the search.
Diagnostic testing for the presence of a known
mutation is usually offered to family members from 
16 years on (the lower age limit to give informed consent
[27, 35]). At this age, the risk of developing symptomatic
DGC is <1% [26]. However, testing should also be
offered to younger HDGC family members, if there is 
a clear benefit to the child and the family. Such families
should be reviewed on a case-by-case basis, considering
the child’s maturity, the anxiety within the family, the severity
of the family history, and the potential for the family to
adjust to future risks associated with a positive test result.
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3 3..2 2  G Ga as st tr ro os sc co op pi ic c  s su ur rv ve ei il ll la an nc ce e
Prophylactic gastrectomy is the only option to prevent
the development and/or spread of HDGC. However, not
every mutation carrier is willing to undergo prophylactic
surgery. This is particularly relevant in young/adolescent
patients and is influenced by concern about the long-
term impact on physical and psychological health, an
issue not well understood. Gastroscopic surveillance is
essential if prophylactic gastrectomy is declined; however,
it must be performed by a gastroenterologist with
experience in HDGC endoscopy (New Zealand HDGC
group, pers. comm.).
Gastroscopic surveillance poses a special problem for
DGC because of its tendency to progress underneath 
a normal appearing gastric mucosa (see section 3.5).
Even advanced stages that involve invasion of extragastric
tissue may not cause a visible distortion of the normal
surface epithelium [36]. Nonetheless, early HDGC stages
that are still restricted to the gastric mucosa can be seen
as pale or sometimes white lesions by the experienced
eye. The lesion pallor can be enhanced by the use of
Congo red and methylene blue during endoscopy. While
this approach has been successful in detecting early
HDGC, the suspected role of Congo red as a carcinogen
limits its routine use [36]. Other potential surveillance
techniques include confocal microscopy and positron
emission tomography, but these remain experimental [37].
In summary, gastroscopic surveillance with standard
white-light endoscopy can detect suspicious lesions when
performed by an experienced gastroenterologist.
However, surveillance is not without risk; therefore
prophylactic gastrectomy is the recommended strategy.
The decision whether a patient should undergo
surveillance or not has to be made in conjunction with
genetic counselling, giving clear advice about the
unquantifiable risk that a cancer may be missed on
endoscopy. Should the patient opt for surveillance,
counselling also needs to include instruction to minimise
exposure to common gastric cancer risk factors such as
salted, cured, preserved foods or smoking, to consume
more fruit and vegetables, and to increase general fitness
[38]. Likewise, mutation carriers need treatment against
H. pylori if infected.
3 3..3 3  P Pr ro op ph hy yl la ac ct ti ic c  g ga as st tr re ec ct to om my y
Total gastrectomy has a perioperative mortality risk
which necessitates careful consideration. Given the young
age of HDGC patients, modern surgical procedures and
improved post-operative care, the operative risk has been
estimated at about 1% [27]. Based on the penetrance
estimates calculated by Pharoah et al. [26], this risk is
matched by the risk of developing symptomatic DGC 
at the age of 20 years in a mutation carrier. Therefore,
the cancer risk outweighs the surgery-associated mortality
risk when delaying prophylactic gastrectomy after the age
of 20 years. Under age 20 years, on the other hand, the
mortality risk from prophylactic gastrectomy is larger than
the risk of developing disease. In addition, total
gastrectomy results in lifelong vitamin B12 deficiency and
malabsorption of vitamins A, D, E, K, folate, calcium and
iron. Elevated levels of osteoporosis, osteomalacia and
malnutrition resulting in weight loss are frequent post-
gastrectomy among gastric cancer patients usually aged
60-70 years [39]. Data on young and adolescent patients
are not available, but gastrectomies are likely to have 
a significant impact on the growth and development in
teenage years. Therefore, in New Zealand prophylactic
gastrectomy is usually not offered to CDH1 mutation
carriers under 18 years of age and not encouraged in
those below 20 years.
3 3..4 4  S Su ur rg gi ic ca al l  p pr ro oc ce ed du ur re e
A meticulous total gastrectomy is mandatory to ensure
all gastric mucosa is removed, which requires particular
care at the esophagogastric junction. The standard
gastrectomy procedure for both asymptomatic patients
and patients with early HDGC detected by surveillance
is D2 dissection with preservation of the spleen and
pancreas, followed by Roux-en-Y esophagojejunostomy
reconstruction without a jejunal pouch reservoir. A Roux-
en-Y reconstruction means food bypasses the duodenum
and a variable length of the proximal jejunum. The
unavailability of intestinal regions, a reduced intestinal
transit time and the absence of a stomach contribute 
to the potential nutritional deficiencies in these patients
(see section 3.3). A more detailed description of surgical
issues is given in refs. [40] and [27].
3 3..5 5  H Hi is st to op pa at th ho ol lo og gi ic ca al l  f fi in nd di in ng gs s  i in n  H HD DG GC C  g ga as st tr re ec ct to om mi ie es s
Despite the absence of symptoms, microscopic
examination of stomachs prophylactically removed from
CDH1 mutation carriers has revealed the presence of
multiple foci of signet-ring cell carcinoma (SRCC)
underneath an intact surface epithelium [41-46]. SRCC
and poorly differentiated carcinoma (PDC) are the two
main subtypes of DGC and are both part of the HDGC
disease phenotype. A variable number (a few to several
hundred) of SRCC foci have been found in almost every
HDGC stomach regardless of the patient’s age. These
foci are always confined to the superficial gastric mucosa
without any nodal involvement (TNM stage T1a), are
usually small (≤1 mm in diameter) and consistH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(4) 188
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F Fi ig g. .   1 1. .   Early tumour stages in HDGC: A A – normal gastric body mucosa; B B – the first apparent disease stage in HDGC is multiple, minute
foci of SRCC confined to the gastric mucosa (stage T1a). SRCs are the predominant cell type in these tumours, are typically located in the
superficial mucosa underneath an intact surface epithelium and are mitotically inactive. Less differentiated and proliferating cancer cells are
found in small numbers deep to the SRCs and are physically close to the gastric neck region; C C – larger foci can acquire an increased amount
of poorly differentiated cancer cells. These cells often have a fibroblastoid appearance consistent with an induction of an epithelial-mesenchymal
transition; D D – invasion through the muscularis mucosae and muscularis propria involves poorly and de-differentiated cancer cells. While
the proliferative activity of stage T1a cancers is very low, more advanced cancers (≥T1b) have a markedly increased proliferation rate
A A B B
C C D D
predominately of signet-ring cells (SRCs) with a few
smaller and less differentiated cells in the deeper part.
Foci that are bigger (≥3 mm) can contain a significant
proportion of poorly differentiated carcinoma cells deep
to the SRCs [47]. It is these larger lesions that can be
detected as pale areas upon endoscopy [36]. Because
these intramucosal SRCC foci seem to be a universal
finding in mutation carriers, they are referred to as early
HDGC (eHDGC).
In contrast to the early HDGC stage, the predominant
histology in advanced HDGC (stage ≥T3, involvement
of serosa and beyond) is that of poorly differentiated
carcinoma [27, 47]. It thus appears that SRCs are typical
of early stage HDGC. In support of this, the only stage
T2 HDGC cancer (with invasion of the muscularis
propria) that has been examined in detail shows the
morphologic spectrum of HDGC, with SRCs in the
superficial mucosa and poorly differentiated cancer cells
deeper down and invading into the muscle layers
underneath [27, 47]. These morphological features
suggest that, in HDGC, progression beyond the gastric
mucosa correlates with the acquisition of a poorly
differentiated cancer cell phenotype. Notably, SRC
histology is also significantly more frequent in early
sporadic DGC compared to advanced stages [48-56].
Figure 1 summarises the early histopathological changes
in HDGC.
3 3..6 6  P Po os st t- -o op pe er ra at ti iv ve e  p pr ro og gn no os si is s
Long-term survival data in HDGC patients post-
gastrectomy are not yet available, but can be estimated
based on survival data in sporadic DGC case series. 
As described in the previous section, HDGC patients 
who have undergone screening or elected to have 
a prophylactic gastrectomy will have eHDGC. A frequent
clinical belief is that diffuse-type carcinoma has a worse
outcome than intestinal-type stomach cancer. Such 
a perception may result from the often delayed diagnosis
of DGC, due to the younger age of onset in DGC
patients and because of the difficulties in detecting early
stage DGC. However, stage-by-stage comparison of
intestinal and diffuse gastric cancer suggests their
outcome is similar [57, 58]. Another widely held belief
is that SRCC has a particularly bad prognosis. Again,
this is not supported by survival data from sporadic DGC
series. Indeed, the majority of studies have found 
a significantly better outcome for early SRCC comparedH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(4) 189
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to other early stage histotypes [48-56]. This is not
surprising when considering molecular data on SRCs (see
section 4.3). In general, the 5-year survival of patients
with early stage SRCC is >90% [53]. Given that these
data also include patients with nodal involvement, the
post-operative prognosis for eHDGC (in the absence of
nodal metastasis) is likely to be excellent. However, it is
important to keep in mind that the risk of CDH1 mutation
carriers developing non-gastric cancers later in their lives
is not known.
3 3..7 7  B Br re ea as st t  c ca an nc ce er r  s sc cr re ee en ni in ng g
Surveillance should be offered to female CDH1
mutation carriers for lobular breast cancer (LBC), the
only other HDGC-associated non-gastric cancer where
penetrance estimates are available (see section 2). Of
the two major forms of breast cancer, ductal and
lobular, the lobular type is more difficult to detect by
virtue of its diffuse growth pattern and relative lack of
microcalcification [59]. Ultrasound and particularly
magnetic resonance imaging (MRI) have been shown
to be better than mammography at detecting invasive
LBC [60-62]. Surveillance protocols for female CDH1
mutation carriers are based on experience with BRCA
mutation family screening [61], where bi-annual clinical
examination and annual mammography combined with
ultrasound/MRI from the age of 35 years onwards is
recommended.
4 4. .   B Bi io ol lo og gy y
4 4..1 1  E E- -c ca ad dh he er ri in n  d do ow wn nr re eg gu ul la at ti io on n  a an nd d  d di is se ea as se e  i in ni it ti ia at ti io on n
The E-cadherin protein encoded by CDH1 is the key
component of the epithelial adherens junction and as
such is essential for proper intercellular adhesion within
epithelial tissues [63]. Loss of E-cadherin has been
documented in many epithelial cancers and is usually
associated with disease progression [64]. In HDGC,
however, E-cadherin deficiency is very likely an initiator
of disease. The protein is consistently downregulated in
the earliest apparent HDGC disease stage [42, 47], the
minute intramucosal SRCCs (see section 3.5). Given that
up to several hundred eHDGC foci can exist in the
stomach of a mutation carrier, it is very improbable that
a gene other than CDH1 is consistently affected. The
uniform downregulation of E-cadherin further indicates
that CDH1 acts as a classic tumour suppressor, requiring
two hits for disease initiation. Potential mechanisms
behind this 2
nd hit include missense mutations, deletions
and epigenetic silencing by promoter hypermethylation
[65, 66]. Of those, the latter appears the most frequent
and has been shown to be present in the earliest disease
stage (B.H. unpublished results). Notably, each eHDGC
focus appears to have a unique CDH1 methylation
pattern (the sequence of methylated and unmethylated
CpG-islands), suggesting that each focus has arisen
independently from a single gastric cell (B.H.,
unpublished results). Of interest, the nature of the 2
nd hit
does not seem to be stochastic; genetic events that
necessarily lead to complete inactivation of both CDH1
alleles have not been demonstrated for HDGC so far
[65, 66], suggesting the 2
nd hit may be selected in a way
that allows some residual CDH1 activity, possibly to
prevent elimination by anoikis [67]. Indeed,
downregulation of E-cadherin below a certain threshold
seems sufficient to abrogate its function [68, 69].
4 4..2 2  M Me ec ch ha an ni is sm ms s  b be eh hi in nd d  t tu um mo or ri ig ge en ne es si is s  d dr ri iv ve en n  b by y  E E- -c ca ad dh he er ri in n
d de ef fi ic ci ie en nc cy y
The loss of adhesion to the epithelial layer that follows
E-cadherin downregulation is thought to be one of the
requirements for the progression to invasive disease [64].
How E-cadherin deficiency may initiate tumour growth is
not well understood. However, adhesive loss has
additional, profound consequences at the cellular level.
The attachment within epithelial planes enables locality
cues required for proper differentiation, is needed for
apical-basal polarity, a distinguishing feature of epithelial
cells, and provides anchor points for the mitotic spindle
apparatus essential for controlled cell division [69-73].
In Drosophila, reduced levels of E-cadherin and the
concomitant loss of polarity have been shown to affect
the orientation of the mitotic spindle and with that the
division plane and the placement of the daughter cell
relative to the epithelial sheet [69]. Similarly, deficient
adherens junctions result in randomisation of spindle
alignment and mis-orientated cell division in the
developing mouse embryo [74]. Cell polarity further
dictates the distribution of cell fate determinants (i.e.
inducers of a specific differentiation pathway) towards
one cell pole [74, 75]. The orientation of the mitotic
spindle may then determine whether the cell fate factors
will be unequally distributed between the daughter cells
(i.e. asymmetric division, where the axis of division dissects
the cell fate gradient), or whether division gives rise to
two equal daughter cells (i.e. symmetric division, where
the divisional axis would be parallel to the cell fate
gradient). Cell fate determination is particularly important
in the context of stem cell biology. Stem cells can
regenerate complete organs due to their unique ability
to produce two daughter stem cells (by symmetric division)
or to produce one daughter stem cell and one committed
progenitor cell (by asymmetric division) that will give rise
to differentiated, organ-specific progeny. A disturbed
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be dangerous and is now thought to lie at the heart of
many malignancies [76]. Several epithelial cancers have
been shown to harbour a subpopulation of so-called
cancer stem cells that are the only cells able to initiate
and maintain successful tumour growth. Similar to normal
stem cells, undifferentiated cancer stem cells can produce
differentiating cancer cells (asymmetric division) or increase
their own pool (symmetric division) for an unlimited time
[76]. The proportion of such cancer stem cells within 
a tumour is believed to determine its aggressiveness 
[77-80]. Given that E-cadherin is essential for cell-cell
adhesion, establishment of polarity, and proper mitotic
spindle orientation, a tempting hypothesis would be that
CDH1 downregulation has a direct effect on the control
of stem cell divisions, providing a basic mechanism
sufficient to drive the development of a tumour.
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Consistent with the hypothesis of a stem cell defect,
the early HDGC foci have an apparent origin at the
upper isthmus, a part of the proliferative zone (the neck
region) of the gastric gland and the presumed location
of the gastric stem cells [47]. Cancer cells close to 
the upper isthmus are proliferative, often not well
differentiated and give rise to the typical SRCs located in
the more superficial mucosa. Typical SRCs, which
represent the vast majority of cells in the foci, stain with
markers of terminally differentiated gastric cells and are
mitotically inactive [47]. Indeed, eHDGC is characterised
by its hypoproliferative state, in contrast to early stages
of many other carcinomas. Another distinct feature is that
eHDGC develops within the lamina propria, meaning
the cancer cells have penetrated the basement
membrane, which classifies these lesions as malignant.
However, the foci do not express invasion-associated
proteins that are observed in more advanced HDGC
(stage ≥T1b, involvement of submucosa and beyond). 
A simple explanation may relate to the observation that
the proliferating cancer cells close to the isthmus initially
develop along the gastric mucous neck cell lineage [47]
which matures into the pepsinogen-producing chief cells.
Pepsinogen is normally secreted into the gastric lumen;
however, the early cancer cells have lost polarity and
would release pepsinogen in all directions, leading to 
a partial digestion of the basement membrane and
providing a window through which the non-adhesive cells
could enter the lamina. Indeed, a significant proportion
of SRCs is positive for circumferential (or unpolarised),
membranous pepsinogen expression (B.H., unpublished
results).
Together, the early HDGC stage is characterised
by its apparent origin from the gastric stem cell region
followed by differentiation to non-dividing SRCs with
a low invasive potential. This indolent state is consistent
with both the long, asymptomatic presence of eHDGC
in CDH1 mutation carriers and the significantly better
prognosis associated with early SRCC (see section 3.6).
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As described in section 3.5, progression of
intramucosal cancer foci to the submucosa correlates
with the acquisition of a poorly differentiated phenotype.
Significant numbers of poorly differentiated cells can be
first observed in larger intramucosal foci and often show
a mesenchymal-like morphology. In contrast to the SRCs,
poorly differentiated cells express activated c-Src kinase,
an established inducer of epithelial-mesenchymal
transitions (EMTs) and of an invasive cancer phenotype.
Activation of c-Src is maintained in more advanced
disease stages, suggesting the kinase is required 
for disease progression [47]. Consistent with c-Src
activation and an EMT, the poorly differentiated cells also
express the c-Src downstream targets Fak, Stat3 and the
mesenchymal marker fibronectin. Other invasion-
associated proteins that can be detected in the poorly
differentiated cells but not in the SRCs include Mmp-2
and Mmp-9 (B.H., unpublished results). Thus, clear
biological differences exist between poorly differentiated
cells and the intramucosal SRCs and support the indolent
nature of the latter cells. These findings also illustrate that
CDH1 downregulation alone (see section 4.3) does not
directly induce an EMT in gastric tissue.
What leads to activation of c-Src kinase and the
induction of an EMT is not known. Data from sporadic
disease suggest that an amplification of 20q, the
region including the c-Src gene, marks the transition
from SRCC to PDC [81]. However, we could not detect
amplification of c-Src in advanced HDGC samples
(BH, unpublished results). Another possibility may
involve progressive DNA methylation that appears to
correlate with poor differentiation in gastric cancer [82]
and may silence inhibitors of c-Src, as has been shown
for caveolin-1 in colorectal cancer [83, 84]. A third
alternative comes from the observation that an EMT
can be seen in larger intramucosal foci. Large foci
appear pale on endoscopy (see section 3.5),
suggesting a reduced blood supply and hypoxic
conditions. Hypoxia can also figure as an inducer of
EMTs [85, 86] and could contribute to the progression
from intramucosal to submucosal disease.
5 5. .   F Fu ut tu ur re e   p pe er rs sp pe ec ct ti iv ve es s
The current clinical management of HDGC by either
endoscopic surveillance or prophylactic gastrectomy has
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drastically reduced the number of deaths due to gastric
cancer in affected families. Neither approach, however,
is perfect. Endoscopic surveillance of diffuse-type gastric
cancer involves the risk of missing a cancer. Although
molecular biology suggests that eHDGC is rather
indolent, the potential of these foci to progress remains
unpredictable. While prophylactic gastrectomy eliminates
this risk, it adds the perioperative risk and may not be the
appropriate strategy in some patients.
Progress is expected with the application of molecular
techniques that will help to describe the biology of SRCs,
poorly differentiated cancer cells, and their surrounding
environment in detail. Such knowledge should enable
the development of in vivo imaging markers targeting
SRCs to improve the sensitivity of endoscopy. A more
sensitive tool for the detection of intramucosal SRCC 
foci would also greatly aid the diagnosis of sporadic
disease. Additional markers specific for invasive, poorly
differentiated cells may also be helpful in selecting patients
for gastrectomy or endoscopic mucosal resection in
sporadic cases.
Though gastric cancer is the 2
nd leading cause of
cancer-related death worldwide, no chemotherapeutic
agents exist which specifically target this malignancy.
However, the molecular investigation of HDGC has
revealed new potential targets likewise applicable to
DGC. c-Src kinase inhibitors are currently in clinical trials
for other malignancies and show a favourable
toxicological profile (see [87] and other refs. in the same
issue). c-Src kinase inhibitors might slow down the
invasion of intramucosal foci into the submucosa and
theoretically could permit gastrectomy to be delayed.
Moreover, the observation that epigenetic events are very
likely to have an aetiological role in HDGC may open
the door to the new class of epigenetic drugs such as
demethylating agents and histone deacetylase inhibitors
[88]. Thus, therapy that is able to revert the neoplastic
phenotype to normality may be feasible.
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